The purpose of this study is to evaluate the safety, tolerability, drug levels, food effects and relative bioavailability of BMS-986365 in healthy male participants.

Inclusion Criteria:

• Healthy adult male participants as determined by no clinically significant deviations from normal in medical history, physical examination, vital signs, ECGs, echocardiogram, or clinical laboratory assessments as determined by the investigator.
• Body mass index (BMI) of 18.0 to 32.0 kg/m^2, inclusive.

Exclusion Criteria:

• Any significant acute or chronic illness.
• Prior history of heart failure, ischemic heart diseases, serious cardiac arrythmias, or prolonged QT interval.
• History of allergy/hypersensitivity to any component (including excipients) of BMS-986365 study interventions or related compounds.
• Other protocol-defined inclusion/exclusion criteria apply.

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria.

Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html